person · Reporting owner

Witz Pascale

Disclosed activity across 4 companies

Tapewire entity: 48571
SEC CIK: 0001703723

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
REVVITY, INC.RVTY · Entity 3382	Director	May 07, 2026	May 11, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

REVVITY, INC.

Report date May 07, 2026 · Filed May 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,985	Ending reported balance After 2026-05-07 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-05-07 · Grant · Acquired 1,015 · Balance 14,720 F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control. Row 2 · 2026-05-07 · Grant · Acquired 1,265 · Balance 15,985

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Horizon Therapeutics Public Ltd Co

Report date October 06, 2023 · Filed October 06, 2023

Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2023-10-06 transaction · row 1 1 source row Row 1 · 2023-10-06 · Disposition to issuer · Disposed 25,672 · Balance 0 F1: 9,349 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly. F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
Ordinary SharesSEC Table I · non-derivative	IndirectBy Trust	Reported balance After 2023-10-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-10-06 · Disposition to issuer · Disposed 20,279 · Balance 0 F1: 9,349 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly. F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.19 · Expires 2027-08-01	Direct	Reported balance After 2023-10-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-10-06 · Disposition to issuer · Disposed 52,232 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F3: The Option (as defined in footnote 4 to this Form 4) is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.87 · Expires 2028-05-02	Direct	Reported balance After 2023-10-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-10-06 · Disposition to issuer · Disposed 32,161 · Balance 0 F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F3: The Option (as defined in footnote 4 to this Form 4) is fully vested.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-07-27	Direct	Reported balance After 2023-10-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-10-06 · Disposition to issuer · Disposed 4,016 · Balance 0 F5: Each RSU (as defined in footnote 7 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F7: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration. F6: The Ordinary Shares subject to the RSUs vest on July 27, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: 9,349 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly.

F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").

F3: The Option (as defined in footnote 4 to this Form 4) is fully vested.

F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option.

F5: Each RSU (as defined in footnote 7 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.

F6: The Ordinary Shares subject to the RSUs vest on July 27, 2024.

F7: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration.

Regulus Therapeutics Inc.

Report date June 25, 2025 · Filed June 27, 2025

Section 16 reporting ended · disclosed 2025-06-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-06-25 transaction · row 1 1 source row Row 1 · 2025-06-25 · Disposition to issuer · Disposed 67,233 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, these Shares were converted into the right to receive the Offer Price. F4: Pursuant to terms of the Merger Agreement, each restricted stock unit that was subject to vesting or forfeiture conditions that was outstanding immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such restricted stock unit immediately prior to the Effective Time by (B) the Closing Amount, plus (ii) one CVR with respect to each Share subject to such restricted stock unit immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.40	Direct	Reported balance After 2025-06-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-06-25 · Disposition to issuer · Disposed 4,650 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.80	Direct	Reported balance After 2025-06-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-06-25 · Disposition to issuer · Disposed 2,325 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F6: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an "Out-of-the-Money Option") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $9.90	Direct	Reported balance After 2025-06-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-06-25 · Disposition to issuer · Disposed 4,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F6: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an "Out-of-the-Money Option") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.70	Direct	Reported balance After 2025-06-25 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-06-25 · Disposition to issuer · Disposed 9,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45	Direct	Reported balance After 2025-06-25 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-06-25 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.36	Direct	Reported balance After 2025-06-25 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-06-25 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.01	Direct	Reported balance After 2025-06-25 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-06-25 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.01	Direct	Reported balance After 2025-06-25 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-06-25 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.
Class A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-06-25 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-06-25 · Disposition to issuer · Disposed 677 · Balance 0 F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time. F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F7: Pursuant to terms of the Merger Agreement, each share of the preferred stock that was outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares into which such shares of preferred stock are convertible immediately prior to the Effective Time, by (B) the Closing Amount; plus (ii) one CVR with respect to each Share into which such shares of preferred stock are convertible immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share.

F2: Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, these Shares were converted into the right to receive the Offer Price.

F4: Pursuant to terms of the Merger Agreement, each restricted stock unit that was subject to vesting or forfeiture conditions that was outstanding immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such restricted stock unit immediately prior to the Effective Time by (B) the Closing Amount, plus (ii) one CVR with respect to each Share subject to such restricted stock unit immediately prior to the Effective Time.

F5: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time.

F6: Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an "Out-of-the-Money Option") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option).

F7: Pursuant to terms of the Merger Agreement, each share of the preferred stock that was outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares into which such shares of preferred stock are convertible immediately prior to the Effective Time, by (B) the Closing Amount; plus (ii) one CVR with respect to each Share into which such shares of preferred stock are convertible immediately prior to the Effective Time.

TESARO, Inc.

Report date January 22, 2019 · Filed January 22, 2019

Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-01-22 transaction · row 1 1 source row Row 1 · 2019-01-22 · Other · Disposed 1,279 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
Director Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-01-22 · Disposition to issuer · Disposed 8,104 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.89 · Expires 2028-06-01	Direct	Reported balance After 2019-01-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-01-22 · Disposition to issuer · Disposed 14,221 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Filing footnotes · ownership attribution and instrument terms

F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").

F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.

F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]

F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 08, 2020 Filed May 12, 2020 20:07 UTC	REVVITY, INC. PKI · Entity 3382	GrantCommon Stock	1,081	$0.00	$0.00	Disclosure SEC source: 0000899243-20-012810 · doc4.xml · nonDerivative · entry 3 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,693 Read SEC document
May 08, 2020 Filed May 12, 2020 20:07 UTC	REVVITY, INC. PKI · Entity 3382	GrantCommon Stock	244	$92.20	$22,496.80	Disclosure SEC source: 0000899243-20-012810 · doc4.xml · nonDerivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,612 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2021, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control. F2 · price: Restricted stock units were awarded in lieu of the reporting person's first 2020 quarterly cash retainer payment, with the number of restricted stock units determined by dividing the amount of the cash retainer payment by the Black-Scholes value of a restricted stock unit on the date the grant was made. Read SEC document
May 08, 2020 Filed May 12, 2020 20:07 UTC	REVVITY, INC. PKI · Entity 3382	GrantCommon Stock	922	$0.00	$0.00	Disclosure SEC source: 0000899243-20-012810 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,368 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2021, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control. Read SEC document
May 02, 2020 Filed May 4, 2020 17:35 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units · Derivative	15,390	$0.00	$0.00	Disclosure SEC source: 0001209191-20-026895 · doc4.xml · derivative · entry 4 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 15,390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On May 2, 2019, the reporting person was granted 15,390 restricted stock units, vesting in full on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 2, 2019, the reporting person was granted 15,390 restricted stock units, vesting in full on the first anniversary of the grant date. Read SEC document
May 02, 2020 Filed May 4, 2020 17:35 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	6,041	$35.62	$215,180.42	Disclosure SEC source: 0001209191-20-026895 · doc4.xml · nonDerivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 29,628 Read SEC document
May 02, 2020 Filed May 4, 2020 17:35 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	15,390	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-026895 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 35,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
April 30, 2020 Filed May 4, 2020 17:35 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantRestricted Stock Units · Derivative	11,098	$0.00	$0.00	Disclosure SEC source: 0001209191-20-026895 · doc4.xml · derivative · entry 3 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,098 Underlying: Ordinary shares · 11,098 shares Expires 2021-04-30 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
December 24, 2019 Filed Dec 26, 2019 08:54 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantCommon Stock Purchase Warrant (Right to Buy) · Derivative	67,700	$0.13 Strike: $0.67	$8,462.50	Disclosure SEC source: 0001209191-19-061857 · doc4.xml · derivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,700 Underlying: Common Stock · 67,700 shares Expires 2024-12-24 F2 · kind: The securities were acquired from the issuer pursuant to a Securities Purchase Agreement dated May 3, 2019. The Securities Purchase Agreement and the issuance of the securities thereunder were approved by the Issuer's Board of Directors and an independent committee thereof. Read SEC document
December 24, 2019 Filed Dec 26, 2019 08:54 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantClass A-2 Convertible Preferred Stock · Derivative	6,770	$6.66	$45,088.20	Disclosure SEC source: 0001209191-19-061857 · doc4.xml · derivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,770 Underlying: Common Stock · 67,700 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock. F2 · kind: The securities were acquired from the issuer pursuant to a Securities Purchase Agreement dated May 3, 2019. The Securities Purchase Agreement and the issuance of the securities thereunder were approved by the Issuer's Board of Directors and an independent committee thereof. F1 · derivative.exercise_date: The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock. F1 · derivative.expiration_date: The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock. Read SEC document
November 21, 2019 Filed Nov 22, 2019 21:05 UTC	REVVITY, INC. PKI · Entity 3382	SaleCommon Stock	1,043	$90.67	$94,568.81	Disclosure SEC source: 0000899243-19-027947 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,446 F1 · price: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $90.66 to $90.68. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
October 10, 2019 Filed Oct 15, 2019 16:49 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantStock Option (Right to Buy) · Derivative	46,500	$0.00 Strike: $0.64	$0.00	Disclosure SEC source: 0001209191-19-053175 · doc4.xml · derivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 Underlying: Common Stock · 46,500 shares Expires 2029-10-09 F1 · derivative.exercise_date: The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service. Read SEC document
August 02, 2019 Filed Aug 5, 2019 17:02 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units · Derivative	8,203	$0.00	$0.00	Disclosure SEC source: 0001209191-19-044613 · doc4.xml · derivative · entry 3 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,204 Underlying: Ordinary shares · 8,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The shares subject to the restricted stock units vest in three equal annual installments on the anniversary of the grant date (August 2, 2017). F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
August 02, 2019 Filed Aug 5, 2019 17:02 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	3,220	$24.64	$79,340.80	Disclosure SEC source: 0001209191-19-044613 · doc4.xml · nonDerivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 20,279 Read SEC document
August 02, 2019 Filed Aug 5, 2019 17:02 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	8,203	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-044613 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 23,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
May 07, 2019 Filed May 8, 2019 17:15 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	PurchaseCommon Stock Purchase Warrant (Right to Buy) · Derivative	29,630	$0.13 Strike: $1.08	$3,703.75	Disclosure SEC source: 0001209191-19-028280 · doc4.xml · derivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,630 Underlying: Common Stock · 29,630 shares Expires 2024-05-07 Read SEC document
May 07, 2019 Filed May 8, 2019 17:15 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	PurchaseCommon Stock	29,630	$1.08	$32,000.40	Disclosure SEC source: 0001209191-19-028280 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,849 Read SEC document
May 07, 2019 Filed May 21, 2019 16:44 UTC Amendment	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantCommon Stock Purchase Warrant (Right to Buy) · Derivative	29,630	$0.13 Strike: $1.08	$3,703.75	Disclosure SEC source: 0001209191-19-031764 · doc4a.xml · derivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,630 Underlying: Common Stock · 29,630 shares Expires 2024-05-07 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof. Read SEC document
May 07, 2019 Filed May 21, 2019 16:44 UTC Amendment	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantCommon Stock	29,630	$1.08	$32,000.40	Disclosure SEC source: 0001209191-19-031764 · doc4a.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,849 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof. Read SEC document
May 03, 2019 Filed May 6, 2019 17:46 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units · Derivative	15,320	$0.00	$0.00	Disclosure SEC source: 0001209191-19-027815 · doc4.xml · derivative · entry 4 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 15,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On May 3, 2018, the reporting person was granted 15,320 restricted stock units, vesting in full on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 3, 2018, the reporting person was granted 15,320 restricted stock units, vesting in full on the first anniversary of the grant date. Read SEC document
May 03, 2019 Filed May 6, 2019 17:46 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	6,014	$26.54	$159,611.56	Disclosure SEC source: 0001209191-19-027815 · doc4.xml · nonDerivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 15,296 Read SEC document
May 03, 2019 Filed May 6, 2019 17:46 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	15,320	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-027815 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 21,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
May 02, 2019 Filed May 6, 2019 17:46 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantRestricted Stock Units · Derivative	15,390	$0.00	$0.00	Disclosure SEC source: 0001209191-19-027815 · doc4.xml · derivative · entry 3 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,390 Underlying: Ordinary shares · 15,390 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
April 30, 2019 Filed May 1, 2019 20:45 UTC	REVVITY, INC. PKI · Entity 3382	GrantCommon Stock	1,043	$0.00	$0.00	Disclosure SEC source: 0000899243-19-011599 · doc4.xml · nonDerivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,489 Read SEC document
April 30, 2019 Filed May 1, 2019 20:45 UTC	REVVITY, INC. PKI · Entity 3382	GrantCommon Stock	785	$0.00	$0.00	Disclosure SEC source: 0000899243-19-011599 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,446 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 30, 2020, which is the first anniversary of the date on which the grant was made. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:58 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative	14,221	Not disclosed Strike: $46.89	Not disclosed	Disclosure SEC source: 0001123292-19-000174 · edgar.xml · derivative · entry 3 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,221 shares Expires 2028-06-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:58 UTC	TESARO, Inc. TSRO · Entity 160894	Disposition to issuerDirector Restricted Stock Units · Derivative	8,104	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-19-000174 · edgar.xml · derivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,104 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document
January 22, 2019 Filed Jan 22, 2019 09:58 UTC	TESARO, Inc. TSRO · Entity 160894	OtherCommon Stock	1,279	$75.00	$95,925.00	Disclosure SEC source: 0001123292-19-000174 · edgar.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). Read SEC document
November 12, 2018 Filed Nov 13, 2018 17:32 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	Disposition to issuerStock Option (Right to Buy) · Derivative	4,583	Not disclosed Strike: $8.76	Not disclosed	Disclosure SEC source: 0001209191-18-058341 · doc4.xml · derivative · entry 4 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,583 shares Expires 2028-05-31 F2 · shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. F4 · price: On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. F6 · derivative.exercise_date: The cancelled option vested in twelve equally monthly installments, such that the option would have been fully vested one year from the date of grant, or the date of the Company's next annual shareholder meeting, whichever occured first. F2 · derivative.underlying_shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
November 12, 2018 Filed Nov 13, 2018 17:32 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	Disposition to issuerStock Option (Right to Buy) · Derivative	6,250	Not disclosed Strike: $8.52	Not disclosed	Disclosure SEC source: 0001209191-18-058341 · doc4.xml · derivative · entry 3 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2028-05-16 F2 · shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. F4 · price: On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. F5 · derivative.exercise_date: The cancelled option provided for vesting in 12 equal monthly installments commencing on the date of grant. F2 · derivative.underlying_shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
November 12, 2018 Filed Nov 13, 2018 17:32 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	Disposition to issuerStock Option (Right to Buy) · Derivative	5,000	Not disclosed Strike: $17.40	Not disclosed	Disclosure SEC source: 0001209191-18-058341 · doc4.xml · derivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-05-30 F2 · shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. F4 · price: On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. F3 · derivative.exercise_date: One third of the shares subject to the cancelled option would have vested on the one year anniversary of the date of grant and the balance of the shares would have vested in a series of 24 equal monthly installments thereafter, such that the option would have been fully vested on the third anniversary of the date of grant. F2 · derivative.underlying_shares: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
November 12, 2018 Filed Nov 13, 2018 17:32 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantCommon Stock	15,833	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-058341 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,625 F1 · price: On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the options listed below in Table II. In exchange for the options cancelled, the reporting person received Restricted Stock Units (RSUs) as reported in this Table I. The RSUs vest ratably on a quarterly basis, such that the the RSUs are fully vested one year after the date of grant, subject to the reporting person's continuous service to Regulus through each vesting date. F2 · balance_after: Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. Read SEC document
November 06, 2018 Filed Nov 7, 2018 21:06 UTC	REVVITY, INC. PKI · Entity 3382	SaleCommon Stock	2,206	$83.62	$184,454.69	Disclosure SEC source: 0000899243-18-028405 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,661 Read SEC document
August 02, 2018 Filed Aug 2, 2018 18:50 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units · Derivative	8,203	$0.00	$0.00	Disclosure SEC source: 0001209191-18-045090 · doc4.xml · derivative · entry 3 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,407 Underlying: Ordinary shares · 8,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The shares subject to the restricted stock units vest in three equal annual installments on the anniversary of the grant date (August 2, 2017). F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
August 02, 2018 Filed Aug 2, 2018 18:50 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	2,213	$18.18	$40,232.34	Disclosure SEC source: 0001209191-18-045090 · doc4.xml · nonDerivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 5,990 Read SEC document
August 02, 2018 Filed Aug 2, 2018 18:50 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	8,203	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-045090 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 8,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
June 01, 2018 Filed Jun 5, 2018 17:08 UTC	TESARO, Inc. TSRO · Entity 160894	GrantDirector Restricted Stock Units · Derivative	4,052	$0.00	$0.00	Disclosure SEC source: 0001104659-18-038346 · a4.xml · derivative · entry 3 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,052 Underlying: Common Stock · 4,052 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of TESARO common stock. F4 · derivative.exercise_date: The RSUs vest in three annual installments beginning on June 1, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors. F4 · derivative.expiration_date: The RSUs vest in three annual installments beginning on June 1, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 01, 2018 Filed Jun 5, 2018 17:08 UTC	TESARO, Inc. TSRO · Entity 160894	GrantDirector Nonqualified Stock Option (right to buy) · Derivative	7,209	$0.00 Strike: $46.89	$0.00	Disclosure SEC source: 0001104659-18-038346 · a4.xml · derivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,209 Underlying: Common Stock · 7,209 shares Expires 2028-06-01 F2 · derivative.exercise_date: The option vests in three annual installments beginning on June 1, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 01, 2018 Filed Jun 5, 2018 17:08 UTC	TESARO, Inc. TSRO · Entity 160894	GrantCommon Stock	1,279	$0.00	$0.00	Disclosure SEC source: 0001104659-18-038346 · a4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 F1 · shares: The Reporting Person has elected to receive common stock in lieu of cash for board retainers and fees otherwise payable in cash. Read SEC document
June 01, 2018 Filed Jun 5, 2018 16:32 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantStock Option (Right to Buy) · Derivative	55,000	$0.00 Strike: $0.73	$0.00	Disclosure SEC source: 0001209191-18-035708 · doc4.xml · derivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2028-05-31 F1 · derivative.exercise_date: The option will vest in twelve equally monthly installments, such that the option will be fully vested one year from the date of grant, or the date of the Company's 2019 annual shareholder meeting, whichever occurs first. Read SEC document
June 01, 2018 Filed Jul 3, 2018 16:56 UTC Amendment	TESARO, Inc. TSRO · Entity 160894	GrantDirector Restricted Stock Units · Derivative	8,104	$0.00	$0.00	Disclosure SEC source: 0001104659-18-043867 · a4a.xml · derivative · entry 3 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,104 Underlying: Common Stock · 8,104 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of TESARO common stock. F5 · shares: This amendment is being filed to amend the Form 4 filed by the reporting person on June 5, 2018 (the "Original Form 4") for the sole purpose of correcting the numbers of derivative securities acquired as reported in column 5 of Table II of the Original Form 4, the numbers of shares underlying securities as reported in column 7 of Table II of the Original Form 4, and the numbers of derivative securities beneficially owned following the reported transactions as reported in column 9 of Table II of the Original Form 4. F4 · derivative.exercise_date: The RSUs vest in three annual installments beginning on June 1, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors. F4 · derivative.expiration_date: The RSUs vest in three annual installments beginning on June 1, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors. F5 · derivative.underlying_shares: This amendment is being filed to amend the Form 4 filed by the reporting person on June 5, 2018 (the "Original Form 4") for the sole purpose of correcting the numbers of derivative securities acquired as reported in column 5 of Table II of the Original Form 4, the numbers of shares underlying securities as reported in column 7 of Table II of the Original Form 4, and the numbers of derivative securities beneficially owned following the reported transactions as reported in column 9 of Table II of the Original Form 4. F5 · balance_after: This amendment is being filed to amend the Form 4 filed by the reporting person on June 5, 2018 (the "Original Form 4") for the sole purpose of correcting the numbers of derivative securities acquired as reported in column 5 of Table II of the Original Form 4, the numbers of shares underlying securities as reported in column 7 of Table II of the Original Form 4, and the numbers of derivative securities beneficially owned following the reported transactions as reported in column 9 of Table II of the Original Form 4. Read SEC document
June 01, 2018 Filed Jul 3, 2018 16:56 UTC Amendment	TESARO, Inc. TSRO · Entity 160894	GrantDirector Nonqualified Stock Option (right to buy) · Derivative	14,221	$0.00 Strike: $46.89	$0.00	Disclosure SEC source: 0001104659-18-043867 · a4a.xml · derivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,221 Underlying: Common Stock · 14,221 shares Expires 2028-06-01 F5 · shares: This amendment is being filed to amend the Form 4 filed by the reporting person on June 5, 2018 (the "Original Form 4") for the sole purpose of correcting the numbers of derivative securities acquired as reported in column 5 of Table II of the Original Form 4, the numbers of shares underlying securities as reported in column 7 of Table II of the Original Form 4, and the numbers of derivative securities beneficially owned following the reported transactions as reported in column 9 of Table II of the Original Form 4. F2 · derivative.exercise_date: The option vests in three annual installments beginning on June 1, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors. F5 · derivative.underlying_shares: This amendment is being filed to amend the Form 4 filed by the reporting person on June 5, 2018 (the "Original Form 4") for the sole purpose of correcting the numbers of derivative securities acquired as reported in column 5 of Table II of the Original Form 4, the numbers of shares underlying securities as reported in column 7 of Table II of the Original Form 4, and the numbers of derivative securities beneficially owned following the reported transactions as reported in column 9 of Table II of the Original Form 4. F5 · balance_after: This amendment is being filed to amend the Form 4 filed by the reporting person on June 5, 2018 (the "Original Form 4") for the sole purpose of correcting the numbers of derivative securities acquired as reported in column 5 of Table II of the Original Form 4, the numbers of shares underlying securities as reported in column 7 of Table II of the Original Form 4, and the numbers of derivative securities beneficially owned following the reported transactions as reported in column 9 of Table II of the Original Form 4. Read SEC document
June 01, 2018 Filed Jul 3, 2018 16:56 UTC Amendment	TESARO, Inc. TSRO · Entity 160894	GrantCommon Stock	1,279	$0.00	$0.00	Disclosure SEC source: 0001104659-18-043867 · a4a.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 F1 · shares: The Reporting Person has elected to receive common stock in lieu of cash for board retainers and fees otherwise payable in cash. Read SEC document
May 17, 2018 Filed May 21, 2018 16:44 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $0.71	$0.00	Disclosure SEC source: 0001209191-18-031898 · doc4.xml · derivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: The option will vest in twelve equally monthly installments, such that the option will be fully vested one year from the date of grant, or the date of the Company's 2019 annual shareholder meeting, whichever occurs first. Read SEC document
May 03, 2018 Filed May 4, 2018 20:06 UTC	REVVITY, INC. PKI · Entity 3382	GrantCommon Stock	1,386	$0.00	$0.00	Disclosure SEC source: 0000899243-18-011501 · doc4.xml · nonDerivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,867 Read SEC document
May 03, 2018 Filed May 4, 2018 20:06 UTC	REVVITY, INC. PKI · Entity 3382	GrantCommon Stock	1,043	$0.00	$0.00	Disclosure SEC source: 0000899243-18-011501 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,481 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on May 3, 2019, which is the first anniversary of the date on which the grant was made. Read SEC document
May 03, 2018 Filed May 7, 2018 17:07 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantRestricted Stock Units · Derivative	15,320	$0.00	$0.00	Disclosure SEC source: 0001209191-18-028370 · doc4.xml · derivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,320 Underlying: Ordinary shares · 15,320 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
May 03, 2018 Filed May 7, 2018 17:07 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantStock Option (Right to Buy) · Derivative	32,161	$0.00 Strike: $13.87	$0.00	Disclosure SEC source: 0001209191-18-028370 · doc4.xml · derivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,161 Underlying: Ordinary shares · 32,161 shares Expires 2028-05-02 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments from the date of grant. Read SEC document
December 04, 2017 Filed Dec 6, 2017 19:39 UTC	Regulus Therapeutics Inc. RGLS · Entity 78034	GrantCommon Stock	60,674	$0.89	$53,999.86	Disclosure SEC source: 0001209191-17-064269 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,674 F1 · shares: Restricted Stock Units (RSUs) issued in lieu of 2018 annual retainer and meeting fees of $54,000. The RSUs vest ratably on a quarterly basis on the last day of each calendar quarter in 2018, subject to the reporting person's continuous service to Regulus. Read SEC document
November 15, 2017 Filed Nov 16, 2017 21:05 UTC	REVVITY, INC. PKI · Entity 3382	GrantCommon Stock	820	$0.00	$0.00	Disclosure SEC source: 0000899243-17-026587 · doc4.xml · nonDerivative · entry 2 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,438 Read SEC document
November 15, 2017 Filed Nov 16, 2017 21:05 UTC	REVVITY, INC. PKI · Entity 3382	GrantCommon Stock	618	$0.00	$0.00	Disclosure SEC source: 0000899243-17-026587 · doc4.xml · nonDerivative · entry 1 Witz Pascale · CIK 0001703723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on November 15, 2018, which is the first anniversary of the date on which the grant was made. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.